Infectious Diseases

When analyzing morbidity data from 2021, investigators found that COVID-19 was among the 10 leading causes of death among children and young people.

Worst of ‘tripledemic’ may be over.

New maternal vaccine options could offer extra protection in upcoming seasons.

The US Food Administration has agreed to review an application for nirsevimab (Beyfortus; AstraZeneca and Sanofi) to protect infants against RSV.

The results show similar rates o colonized C difficile among pediatric patients and adult patients with cystic fibrosis.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief of Contemporary Pediatrics, talks about the most significant moments in children’s health in 2022; what the tridemic really means for pediatric health care providers; and what we have to look forward to in 2023 when it comes to new vaccines and medications.

Alok Patel, MD, shares what pediatric health care providers should know about a concerning new strain of group A streptococcus.

New surveillance data from the 2021-22 influenza show the impact of coinfection among younger patients.

Steven Selbst, MD, pediatric emergency medicine physician at Nemours Children's Health, discusses the surge of RSV cases and hospitalizations this season.

In a recent statement, the American Academy of Pediatrics discussed how patients with respiratory infections can be managed, along with guidance on RSV treatment.

Tell your patients to get their annual flu vaccines for best protection against illness.

In a recent study, investigators found that life-threatening neurologic conditions from severe acute COVID-19 were more frequent in 2021 than 2020.

In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.

A real-world study determined the efficacy of mRNA vaccines for protection against COVID-19 in adolescents.

Infants born to mothers with COVID-19 infection during pregnancy often experienced positive birth outcomes from April 2020 to October 2020, and COVID-19 transmission was rare.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discussed the potential threat of a “triple epidemic” of RSV, influenza, and COVID-19, and how pediatricians can identify these viruses in their communities.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the rising threat of a "triple epidemic" consisting of influenza, COVID-19, and RSV in children.

Pfizer announced positive data from a phase 3 trial on a bivalent RSV vaccine.

In 2022, Chile saw an influenza season with atypical timing and severity, indicating similar cases may occur in regions such as the United States.

In a simulated back-to-school trial, rate of hand-to-face contact among students wearing face masks did not differ from those without face masks, and risk of infection did not increase.

CDC, other experts are tracking increases in respiratory syncytial virus cases in infants.

At IDWeek 2022, Taylor Wells, MD, gave a presentation on how long COVID affects the pediatric population.

Deborah Molrine, MD, Clinical Program Director, QIVc at CSL Seqirus, discusses CSL Seqirus’ cell-based quadrivalent seasonal influenza vaccine, along with the effectiveness of cell-based vaccines in children.

As COVID-19 continues to spread, vaccinations remain available to protect children from severe disease, hospitalization, and death.

At the 2022 American Academy of Pediatrics National Conference & Exhibition, research was presented on which children are at high risk of severe COVID-19.

In this article, declining trends in vaccination across the United States are discussed, along with how providers can reduce vaccine hesitancy.

At the 2022 AAP National Conference & Exhibition, a professor of pediatrics describes the benefits of COVID-19 vaccines for children, safety considerations, and urges physicians to continue to urge caregivers to get their children vaccinated.

In a session at the 2022 AAP National Conference & Exhibition, a physician presenter enumerates unique challenges in treating emerging infectious diseases in children and takes a look at the current pediatric COVID-19 therapies—and evidence gaps.

At the 2022 AAP National Conference & Exhibition, one session reviews pediatric considerations for dosing, safety, and regulatory approval for medications and vaccines for SARS-CoV-2, and a look at the Pediatric Trials Network.

At the 2022 AAP National Conference & Exhibition in Anaheim, California, Rana E. El Feghaly, MD, MSCI, associate professor, University of Missouri-Kansas City, Children's Mercy Kansas City, Missouri, led a session on how pediatric clinicians can employ best practices when prescribing medications for common childhood infections.